Hemodiafiltration Emerges as Transformative Dialysis Therapy in US

For nearly three decades, American nephrologists have watched their European counterparts refine a dialysis technique called hemodiafiltration, waiting for evidence that would justify bringing it home. That evidence arrived a few years ago in the form of the CONVINCE trial, which showed that patients receiving high-volume hemodiafiltration experienced a mortality improvement of more than 20 percent compared to those on standard dialysis. The finding landed like a rare thunderclap in a field accustomed to incremental progress. Now, for the first time in a generation, the machinery of American kidney care—the major dialysis providers, the professional societies, the regulatory bodies—is beginning to move.

The last major advance in dialysis care arrived in the 1990s. Nephrologists switched from acetate to bicarbonate as a buffer, introduced polysulfone membranes, gained better control over ultrafiltration, and deployed erythropoiesis-stimulating agents to combat anemia. Since then, the field has largely held steady. Michael Anger, who works in the global medical office at Fresenius Medical Care, one of the two largest dialysis providers in the United States, described the drought plainly: advances that truly move the needle for patients have been "pretty few and far between." Hemodiafiltration represents something different—a therapy with international pedigree, robust clinical data, and the potential to reduce not just mortality but hospitalizations and improve how patients actually feel.

The panel convened by Joel Topf, a nephrologist at Henry Ford Health, and Anna Gaddy, an associate professor at the Medical College of Wisconsin, included Jeff Giullian, chief medical officer at DaVita, the nation's largest dialysis operator; Anger; and Keith Bellovich, a Detroit-based nephrologist who leads Strive Health and chairs the Kidney Care Partners coalition—an alliance of professional societies, patient organizations, dialysis providers of all sizes, and pharmaceutical companies united around kidney care policy. Bellovich's role proved significant to the conversation. Kidney Care Partners exists precisely to coordinate advocacy around issues that affect the entire dialysis ecosystem, and hemodiafiltration has become one of them.

What makes this moment different from past technological transitions is the weight of the evidence and the breadth of the push. Giullian, who entered nephrology as the field was adopting high-flux dialyzers, noted that even that shift happened without definitive proof of benefit. The HEMO trial, a major randomized study, included a comparison of low-flux versus high-flux dialysis and found no meaningful difference in outcomes. The profession moved to high flux anyway, driven by intuition and incremental data. Hemodiafiltration arrives with something stronger: a landmark trial showing substantial mortality reduction. Anger emphasized that while other randomized controlled trials preceded CONVINCE, that trial was "the definitive one" that catalyzed North American attention. Some hemodiafiltration had been performed in the United States before, but primarily in acute settings on continuous renal replacement therapy. Outpatient hemodiafiltration—the setting where most American dialysis patients receive treatment—remained largely absent until CONVINCE shifted the conversation.

Bellovich offered a historical parallel that suggested how these transitions ultimately succeed. When dialysis centers abandoned reuse of dialyzer membranes, the shift followed a predictable pattern: techniques improved, costs eventually outweighed the benefits of reuse, and the practice faded. The same logic, he suggested, would eventually apply to hemodiafiltration. Once the technology matures and implementation becomes feasible, the economics will align, and adoption will spread across the entire patient population rather than remaining confined to specialized centers or early adopters.

Yet the path from trial data to widespread availability remains uncertain. Gaddy posed the question that animated the entire discussion: Is hemodiafiltration something American patients will actually get, or will it remain a tool that exists elsewhere, discussed at conferences but never quite reaching the clinic? The enthusiasm among the panelists was genuine, but so was the acknowledgment that enthusiasm alone does not move therapy into practice. Regulatory pathways must be navigated. Reimbursement models must be established. The economics of implementation across thousands of dialysis centers—large corporate operations, medium-sized chains, and small independent practices—must pencil out. The technology must be integrated into existing workflows without disrupting care for the hundreds of thousands of Americans already on dialysis.

What distinguishes this moment from the long wait that preceded it is that the major players are no longer passive. DaVita and Fresenius, which together dominate American dialysis, have representatives actively engaged in the conversation. Professional organizations are coordinating. The data is unambiguous. For a field that has measured progress in decades between meaningful advances, the alignment of evidence, institutional interest, and regulatory attention suggests that the long European experiment with hemodiafiltration may finally be coming to American dialysis centers. The question now is not whether it will happen, but how quickly and at what scale.